AstraZeneca Says Imfinzi Improved Pathologic Complete Response in Lung Cancer
30 Junio 2022 - 1:43AM
Noticias Dow Jones
By Jaime Llinares Taboada
AstraZeneca PLC said Thursday that Imfinzi combined with
chemotherapy significantly improved pathologic complete response in
patients with resectable lung cancer.
The pharmaceutical company reported positive results from an
interim analysis of Phase III trials, as the treatment also caused
a significant improvement in major pathologic response.
The trial will continue as planned to assess the additional
primary endpoint of event-free survival.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com;
@JaimeLlinaresT
(END) Dow Jones Newswires
June 30, 2022 02:28 ET (06:28 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Astrazeneca (LSE:AZN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024